A

Agios Pharmaceuticals
D

AGIO

39.530
USD
0.44
(1.13%)
مغلق
حجم التداول
52,220
الربح لكل سهم
-7
العائد الربحي
-
P/E
3
حجم السوق
2,289,387,816
أصول ذات صلة
C
CRSP
-1.100
(-1.83%)
59.000 USD
E
EDIT
-0.01500
(-0.49%)
3.06000 USD
N
NTLA
0.030
(0.25%)
12.155 USD
Q
QURE
0.000
(0.00%)
14.890 USD
R
RARE
-10.380
(-25.05%)
31.050 USD
S
SGMO
-0.03090
(-5.82%)
0.50000 USD
S
SRPT
-0.300
(-1.55%)
19.060 USD
المزيد
الأخبار المقالات

العنوان: Agios Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.